A Phase III Trial of Pembrolizumab as Adjuvant Treatment for Renal Cell Carcinoma
Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the phase III KEYNOTE-564 trial of pembrolizumab (Keytruda) as adjuvant treatment for renal cell carcinoma (RCC). <br />
Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the phase III randomized KEYNOTE-564 trial of pembrolizumab (Keytruda) as adjuvant treatment for renal cell carcinoma (RCC).
This study is currently in progress, and started accruing patients earlier this year. The primary endpoint of the study is disease-free survival. Investigators are aiming to enroll high-risk patients with high-risk features. As there are currently no standard of care treatments in the adjuvant setting of kidney cancer, this study, as well as several other ongoing studies, aim to improve adjuvant treatment for these patients, Zhang says.
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Deciding Factors for Front-Line Therapy in Metastatic RCC
April 17th 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic renal cell carcinoma in the first article of a 2-part series.
Read More
